Loading...
XSHE
000963
Market cap10bUSD
May 22, Last price  
42.34CNY
1D
0.57%
1Q
20.11%
Jan 2017
76.27%
Name

Huadong Medicine Co Ltd

Chart & Performance

D1W1MN
P/E
26.15
P/S
1.84
EPS
1.62
Div Yield, %
2.20%
Shrs. gr., 5y
-0.07%
Rev. gr., 5y
5.67%
Revenues
40.39b
+7.10%
2,882,475,1603,484,232,5893,942,455,3214,853,413,4206,016,486,1417,824,872,1648,971,836,50911,131,372,42214,579,230,37416,717,986,44618,947,379,09421,727,383,49425,379,667,50227,831,823,14830,663,374,32635,445,698,21633,683,058,75934,563,301,23337,714,587,45840,391,192,251
Net income
2.84b
+13.59%
30,581,43167,313,91883,351,285173,160,209168,609,741378,421,189317,306,761381,484,999469,927,239574,975,854756,669,4191,096,912,4321,446,591,6981,779,506,0612,267,229,1742,813,118,7022,819,861,2032,301,631,3472,499,214,3592,838,860,542
CFO
3.93b
+64.96%
12,506,256203,330,80857,380,441265,790,560344,689,663567,939,912016,123,655642,729,226476,977,321740,854,724658,536,2561,346,962,8071,661,118,6632,039,496,0832,001,698,1703,411,447,7473,169,757,8672,381,852,6683,929,216,706
Dividend
Sep 20, 20240.35 CNY/sh

Profile

Huadong Medicine Co., Ltd produces and sells various pharmaceutical products in China. It offers Chinese patent drugs, immunosuppressive agents, endocrine drugs, digestive system drugs, antineoplastic drugs, cardiovascular drugs, medical cosmetology, and antibiotic drugs, as well as medical equipment. The company's products include gastrointestinal agents, APIs, and other products. It also engages in the production and management of traditional Chinese and western raw medicines and preparations, and health care products; wholesale of TCM materials, TCM decoction pieces, chemical preparations, etc.; warehousing and storage business; and research, development, production, and sale of aesthetic medicine products. Huadong Medicine Co., Ltd was founded in 1993 and is headquartered in Hangzhou, China.
URL
https://www.eastchinapharm.com/
IPO date
Jan 27, 2000
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
40,391,192
7.10%
37,714,587
9.12%
Cost of revenue
34,212,940
33,557,266
Unusual Expense (Income)
NOPBT
6,178,252
4,157,321
NOPBT Margin
15.30%
11.02%
Operating Taxes
619,589
498,499
Tax Rate
10.03%
11.99%
NOPAT
5,558,663
3,658,822
Net income
2,838,861
13.59%
2,499,214
8.58%
Dividends
(594,215)
(507,445)
Dividend yield
0.82%
0.62%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
822,380
1,095,352
Long-term debt
634,150
1,220,678
Deferred revenue
42,077
126,124
Other long-term liabilities
320,586
398,674
Net debt
(5,320,726)
(3,713,908)
Cash flow
Cash from operating activities
3,929,217
2,381,853
CAPEX
(1,606,618)
Cash from investing activities
(1,820,068)
Cash from financing activities
(1,418,361)
FCF
5,414,475
2,607,175
Balance
Cash
4,663,378
3,996,302
Long term investments
2,113,878
2,033,636
Excess cash
4,757,696
4,144,208
Stockholders' equity
17,983,032
17,042,173
Invested Capital
18,587,066
17,358,993
ROIC
30.93%
23.02%
ROCE
26.26%
19.15%
EV
Common stock shares outstanding
1,751,626
1,749,810
Price
41.45
-11.43%
46.80
16.42%
Market cap
72,604,905
-11.34%
81,891,087
16.42%
EV
67,818,834
78,775,701
EBITDA
6,996,599
4,862,870
EV/EBITDA
9.69
16.20
Interest
144,200
125,100
Interest/NOPBT
2.33%
3.01%